The hybrid conference will be held
“Presentations at ASM Microbe provide data from two key studies that further explore the potential of NUZYRA as an option for the treatment and post-exposure prophylaxis in the event of an anthrax bioterror attack,” said
NUZYRA presentation details:
Presentation Title: Omadacycline Efficacy in a Post-Exposure Prophylaxis Mouse Model of Inhalational Anthrax Caused by Ciprofloxacin-Resistant Bacillus anthracis
Presentation type/category: Poster Spotlight Session PT002 – Expanding the clinical utility of marketed antibiotics
Presenter:
Time/Location:
Presentation type/category: Poster Session P085-AAR08 – New Antimicrobial Agents: New Non-Small Molecules & Existing Agents (AAR-Saturday-522)
Presenter:
Time/Location:
Presentation Title: Omadacycline is Efficacious in a Treatment Model of Inhalational Anthrax in
Presentation type/category: Poster Session P085-AAR08 – New Antimicrobial Agents: New Non-Small Molecules & Existing Agents (AAR-Saturday-526)
Presenter:
Time/Location:
Presentation Title: In vitro Activity of Omadacycline against Clin. Isolates of Nocardia*
Presentation type/category: Poster session P085-AAR08 – New Antimicrobial Agents: New Non-Small Molecules & Existing Agents (AAR-Saturday-520)
Presenter:
Time/Location:
*
About
The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in
Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential
Paratek exclusively licensed
In 2019, Paratek was awarded a contract from the
For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.
About NUZYRA®
NUZYRA® (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals and other drug-resistant strains.
Forward Looking Statements
This press release contains forward-looking statements related to our presentations of data from non-clinical and microbiology programs, including the utility, durability and safety of NUZYRA across a broad range of serious, community-acquired infections. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended
CONTACTS:
For Investors:
PJ Kelleher
pkelleher@lifesciadvisors.com
617-430-7579
For Media:
Scient PR
Christine@ScientPR.com
215-595-5211
Source:
2023 GlobeNewswire, Inc., source